Last reviewed · How we verify
RNF
RNF is a small molecule targeting the CD47/SIRPα axis.
RNF is a small molecule targeting the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma, Relapsed or refractory non-Hodgkin lymphoma.
At a glance
| Generic name | RNF |
|---|---|
| Also known as | Rebif®, Rebif |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | CD47/SIRPα inhibitor |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
RNF works by blocking the interaction between CD47 and SIRPα, which is a mechanism that cancer cells use to evade immune detection. This blockade allows the immune system to recognize and attack cancer cells more effectively.
Approved indications
- Relapsed or refractory multiple myeloma
- Relapsed or refractory non-Hodgkin lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Promoting Positive Care Interactions (PPCI) in Assisted Living (NA)
- Oral Cladribine in Early Multiple Sclerosis (MS) (PHASE3)
- A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) (PHASE2)
- Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (PHASE3)
- Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis (PHASE3)
- A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects
- A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis (PHASE3)
- An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RNF CI brief — competitive landscape report
- RNF updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI